Search Result

Results for "

Antibiotic resistance

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (44) P-glycoprotein (11) Aminoacyl-tRNA Synthetase (3) Apoptosis (9) Arginase (2) Bacterial (81) Bcl-2 Family (8) Beta-lactamase (7) Calcium Channel (1) Caspase (8) Dihydrofolate reductase (DHFR) (1) DNA/RNA Synthesis (6) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (1) Endogenous Metabolite (13) Environmental Pollutants (1) Fungal (2) FXR (8) G protein-coupled Bile Acid Receptor 1 (8) Interleukin Related (1) Isotope-Labeled Compounds (5) LPL Receptor (8) MDM-2/p53 (8) Nucleoside Antimetabolite/Analog (1) Parasite (4) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) TNF Receptor (1) Topoisomerase (5)
By Research Areas:	Cancer (15) Endocrinology (1) Infection (79) Inflammation/Immunology (5) Metabolic Disease (11) Neurological Disease (1)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (1)

Inhibitors & Agonists

Bibliotecas de Screening

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Antibiotic BCRP P-glycoprotein

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-N1423

Glycocholic acid 3 Publications Verification	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor	Metabolic Disease Inflammation/Immunology Cancer
Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-B1329

Apramycin sulfate 4 Publications Verification Nebramycin II sulfate	Bacterial Antibiotic	Infection
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside *antibiotic* which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .

HY-B1455

Clindamycin 10+ Cited Publications	Bacterial Antibiotic Parasite	Infection Cancer
Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide *antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus* at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-103251

PF-5081090 LpxC-4	Antibiotic Bacterial	Infection
PF-5081090 (LpxC-4) is a potent LpxC inhibitor, is a rapidly bactericidal with broad-spectrum activity. PF-5081090 serves as a regulator of lipid A biosynthesis in Gram-negative pathogens .

HY-W062216

2-Aminoimidazole	Bacterial Arginase	Infection
2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a K_i of 3.6 mM .

HY-77641

Cinnamoylglycine	Endogenous Metabolite	Metabolic Disease
Cinnamoylglycine is a human urinary metabolite and PPG analog. Cinnamoylglycine is a conjugate of cinnamic acid and glycine. Cinnamoylglycine is used as a urine marker. Cinnamoylglycine can be used in adipogenic differentiation studies .

HY-116815

Lalistat 1 2 Publications Verification	Beta-lactamase Bacterial	Infection Neurological Disease
Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC₅₀ of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .

HY-17028

Besifloxacin Hydrochloride	Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Besifloxacin Hydrochloride is a fourth generation fluoroquinolone *antibiotic. Besifloxacin Hydrochloride is a DNA gyrase* and topoisomerase IV inhibitor. Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research .

HY-N1423A

Glycocholic acid sodium 3 Publications Verification	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite	Metabolic Disease Cancer
Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-B1325

Cefuroxime axetil	Bacterial Antibiotic	Infection Inflammation/Immunology
Cefuroxime axetil is an orally effective broad-spectrum β-lactam antibiotic that targets bacterial penicillin-binding proteins (PBPs, such as PBP3 and PBP1). Cefuroxime axetil inhibits cell wall synthesis, leading to bacterial lysis and death, with a minimum inhibitory concentration (MIC) of 0.12-4 mg/L for non-typeable Haemophilus influenzae (NTHi). Cefuroxime axetil is hydrolyzed by esterase to the active ingredient Cefuroxime (HY-B1256A) after oral absorption. Topical administration of Cefuroxime via bioadhesive nanoparticles (BNPs) can prolong the drug's retention time in the middle ear (≥7 days). Cefuroxime axetil can be used in the study of otitis media (especially NTHi infection). Cefuroxime axetil can achieve precise antibacterial effects through oral or topical nano-delivery systems, reducing systemic exposure and the risk of antibiotic resistance .

HY-N1423S

Glycocholic acid-d4	Isotope-Labeled Compounds P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor	Metabolic Disease Cancer
Glycocholic acid-d₄ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-P3078

Amphomycin	Bacterial Antibiotic	Infection
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .

HY-112589

BRITE-338733	Bacterial	Infection Cancer
BRITE-338733 is an inhibitor of E. coli RecA ATPase activity (IC₅₀: 4.7 μM). BRITE-338733 also inhibits the ATP hydrolysis activity of RSC chromatin remodeling enzyme by binding to its ATP-binding pocket and DNA (IC₅₀: 0.316 μM). BRITE-338733 exhibits cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cells. BRITE-338733 can be used in studies on antibacterial adjuvants and anticancer research .

HY-106681

Lagosin Fungichromin; Pentamycin; Cogomycin	Antibiotic Fungal	Cancer
Lagosin (Fungichromin) is a polyene macrolide antibiotic. Lagosin has demonstrated broad-spectrum antifungal activity and is impervious to agent resistance .

HY-122071

Bicyclomycin	Antibiotic Bacterial	Infection
Bicyclomycin is an *antibiotic. Bicyclomycin exhibits selective antibacterial activity against Gram-negative bacteria such as Escherichia coli* and Klebsiella spp., with no cross-resistance. Bicyclomycin is applicable to the research of infectious diseases .

HY-127146

Platensimycin	Antibiotic Bacterial	Infection
Platensimycin is an *antibiotic* produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC₅₀=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC₅₀s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance.

HY-139398

TBI-223 1 Publications Verification	Antibiotic Bacterial	Infection
TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb). TBI-223 exhibits an IC₅₀ of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis .

HY-W013105

Sodium glycocholate hydrate, 98% N-Cholylglycine sodium salt, 98%	Bcl-2 Family Caspase Endogenous Metabolite Bacterial MDM-2/p53 P-glycoprotein LPL Receptor FXR G protein-coupled Bile Acid Receptor 1 Apoptosis	Others
Sodium glycocholate hydrate, 98% is a bile acid derivative. Sodium glycocholate hydrate, 98% downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Sodium glycocholate hydrate, 98% inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Sodium glycocholate hydrate, 98% modulates related bile acid receptor signaling. Sodium glycocholate hydrate, 98% suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Sodium glycocholate hydrate, 98% can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-152296

8-Methyladenosine	Nucleoside Antimetabolite/Analog Bacterial	Infection
8-Methyladenosine is a modified adenosine nucleoside. Through methylation at the 8-position, 8-Methyladenosine confers bacterial resistance to five classes of antibiotics that bind to the ribosomal peptidyl transferase center. 8-Methyladenosine can be used in studies of antibiotic-resistant bacterial infections .

HY-P1674A

Murepavadin TFA 3 Publications Verification POL7080 TFA	Bacterial Antibiotic	Infection
Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific *antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa* with MIC₅₀ and MIC₉₀ values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .

HY-N1423B

Glycocholic acid hydrate 3 Publications Verification	Endogenous Metabolite Caspase G protein-coupled Bile Acid Receptor 1 LPL Receptor MDM-2/p53 Bcl-2 Family P-glycoprotein FXR Bacterial Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Glycocholic acid hydrate is a bile acid derivative. Glycocholic acid hydrate downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid hydrate inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid hydrate modulates related bile acid receptor signaling. Glycocholic acid hydrate suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid hydrate can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-P1674

Murepavadin POL7080	Bacterial Antibiotic	Infection
Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific *antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa* with both MIC₅₀ and MIC₉₀ values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .

HY-126906

Milbemycin A4	Environmental Pollutants Antibiotic P-glycoprotein	Cancer
Milbemycin A4 inhibits P-glycoprotein activity, and reverses multidrug resistance of tumor cells. Milbemycins are a family of macrolide antibiotics with insecticidal and acaricidal activity sup>[2].

HY-161685

Antibiofilm agent-8	Bacterial Reactive Oxygen Species (ROS) Endogenous Metabolite	Infection
Antibiofilm agent-8 (compound Ru2) enhances antimicrobial activity on visible-light exposure (400-700 nm, 10 J cm-2). Antibiofilm agent-8 generates of oxidative stress via NADH oxidation and ROS generation and compromises bacterial wall .

HY-B1329R

Apramycin sulfate (Standard) Nebramycin II sulfate (Standard)	Reference Standards Bacterial Antibiotic	Infection
Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .

HY-159687

Nafithromycin WCK 4873	Antibiotic Bacterial	Infection
Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC₉₀ of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter .

HY-B1455S1

Clindamycin-13C,d3	Isotope-Labeled Compounds Bacterial Antibiotic Parasite	Infection
Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-N7118

Clindamycin hydrochloride monohydrate	Bacterial Antibiotic	Infection Cancer
Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .

HY-P10027

Clovibactin	Antibiotic Bacterial	Infection
Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .

HY-17558

Apramycin 4 Publications Verification Nebramycin II	Bacterial Antibiotic	Infection
Apramycin (Nebramycin II) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside *antibiotic* which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .

HY-77641S

Cinnamoylglycine-d2	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Cinnamoylglycine-d₂ is the deuterium labeled Cinnamoylglycine. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment .

HY-P10027A

Clovibactin TFA	Antibiotic Bacterial	Infection
Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .

HY-126906R

Milbemycin A4 (Standard)	Reference Standards Antibiotic P-glycoprotein	Cancer
Milbemycin A4 (Standard) is the analytical standard of Milbemycin A4. This product is intended for research and analytical applications. Milbemycin A4 inhibits P-glycoprotein activity, and reverses multidrug resistance of tumor cells. Milbemycins are a family of macrolide antibiotics with insecticidal and acaricidal activity sup> .

HY-144659

Metallo-β-lactamase-IN-5	Beta-lactamase Apoptosis Bacterial	Infection
Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC₅₀ of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .

HY-178347

Debio 1453	Bacterial	Infection
Debio 1453 is a bactericidal FabI inhibitor potent against N. gonorrhoeae (IC₅₀ = 0.6 nM), including drug-resistant strains. Debio 1453 demonstrates a low propensity for resistance selection and is effective in eradicating both planktonic and intracellular bacteria through a mechanism of concurrently inhibiting FabI and engaging the non-mutable NADH cofactor. Debio 1453 clears antibiotic-resistant N. gonorrhoeae infection in a murine vaginal model. Debio 1453 can be used for gonorrhoea research .

HY-P10209

Cilagicin	Antibiotic Bacterial	Infection
Cilagicin, a dodeca-lipodepsipeptide, is a Gram-positive active *antibiotic. Cilagicin has a dual polyprenyl phosphate binding mechanism that impedes resistance* development .

HY-146330

FtsZ-IN-2	Bacterial	Infection
FtsZ-IN-2 (Compound 19) is an inhibitor of the bacterial cell division protein FtsZ with GTPase inhibitory activity. FtsZ-IN-2 exhibits anti-staphylococcal activity with MIC values of 2 µg/ml for MSSA and MRSA .

HY-130337

Teicoplanin A2-2	Antibiotic Bacterial	Infection
Teicoplanin A2-2 is a glycopeptide *antibiotic. Teicoplanin A2-2 exhibits antibacterial activity, particularly against coagulase-negative staphylococci (CNS). Teicoplanin A2-2 inhibits bacterial cell wall synthesis by competitively binding to the terminal D-Ala-D-Ala peptide bonds in the cell wall synthesis process, leading to bacterial death. Teicoplanin A2-2 can be used for research into bacterial resistance* mechanisms and the development of new antibiotics .

HY-106922

Sanfetrinem GV104326	Antibiotic Bacterial	Infection
Sanfetrinem (GV104326) is a β-lactamase-stable antibiotic. Sanfetrinem has broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria .

HY-B1455S

Clindamycin-d3 hydrochloride	Bacterial Antibiotic Parasite	Infection
Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-178504

Lug-15	Bacterial	Infection
Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .

HY-178952

Anti-infective agent 12	Bacterial	Infection
Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidease (SPase I), with an IC₅₀ of 4.475 μM and a K_d of 16.3 μM. Anti-infective agent 12 has the ability to disrupt bacterial membranes and remove biofilms. Anti-infective agent 12 exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus suis, respectively. Anti-infective agent 12 remains effective against multi-drug resistant strains, but has weaker activity against Gram-negative bacteria (such as Escherichia coli and Salmonella), with MIC values > 64 μg/mL. Anti-infective agent 12 has low hemolytic activity and shows significant efficacy in mouse skin infection models .

HY-B0317F

Amlodipine hydrochloride	Calcium Channel	Infection
Amlodipine hydrochloride is a biologically active drug used to lower blood pressure and prevent chest pain. Amlodipine hydrochloride has shown synergistic effects with antimicrobial drugs in in vitro studies, especially against carbene peptide-resistant Acinetobacter baumannii. Amlodipine hydrochloride can be used in combination with other antibiotics to enhance the inhibitory effect against resistant bacteria. The use of amlodipine hydrochloride helps reduce the dosage requirements of the drug, reduce toxic effects, and delay the emergence of drug resistance .

HY-106998

DC-756	Bacterial Antibiotic	Infection
DC-756 is a fluoroquinolone antibiotic. DC-756 possesses potent activity against Gram-positive and Gram-negative pathogens comparable to Trovafloxacin (HY-A0170), with MIC, against Ofloxacin (HY-B0125)-resistant strains 16-fold better than Trovafloxacin. DC-756 is well absorbed orally in rats and found to have good photostability. DC-756 can be used to study bacterial resistance .

HY-147674

Isoleucyl tRNA synthetase-IN-2	Aminoacyl-tRNA Synthetase	Infection
Isoleucyl tRNA synthetase-IN-2 (compound 36a) is a potent and selective isoleucyl-tRNA synthetase (IleRS) inhibitor, with a K_i,app of 114 nM .

HY-122699

LN-1-255 sodium	Beta-lactamase Bacterial	Infection
LN-1-255 sodium is a β-lactamase inhibitor. LN-1-255 sodium has broad-spectrum inhibitory effect on type D carbapenemases (CHDLs) with an IC₅₀ for OXA-48 of 3 nM, and it also has strong activity against OXA-23, OXA-24/40, etc. LN-1-255 sodium combined with carbapenem antibiotics has a synergistic effect. LN-1-255 sodium can be used to study the bacterial resistance crisis caused by CHDLs .

HY-N1423S1

Glycocholic acid-d5	Isotope-Labeled Compounds P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor	Metabolic Disease Cancer
Glycocholic acid-d₅ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-W751579

Cefovecin	Bacterial Antibiotic	Infection
Cefovecin is a third-generation cephalosporin antibiotic. Cefovecin's most notable characteristic is its extremely long-lasting effect; a single subcutaneous injection can maintain an effective therapeutic concentration in tissues for up to 14 days. Cefovecin is used in research on bacterial infections in dogs and cats .

HY-103251R

PF-5081090 (Standard) LpxC-4 (Standard)	Reference Standards Antibiotic Bacterial	Infection
Cefalonium (dihydrate) (Standard) is the analytical standard of Cefalonium (dihydrate). This product is intended for research and analytical applications. Cefalonium dihydrate is a cephalosporin antibiotic. Cefalonium (dihydrate) is effective against Staphylococcus aureus. Cefalonium (dihydrate) has anti-inflammatory and antibacterial activities .

HY-146199

Antibacterial agent 108	Bacterial	Infection
Antibacterial agent 108 (Compound 1h) is a potent antibacterial agent with a MIC of both 3 μM against MRSA and antibiotic resistance strains .

Cat. No.	Nombre del producto

HY-L169

Anti-Drug-Resistant Compound Library

662 compounds

Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.

MCE designs a unique collection of 662 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.

HY-L219

Antimicrobial Peptides Library

58 compounds

Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development.

MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.

Cat. No.	Nombre del producto	Type

HY-W013105

Sodium glycocholate hydrate, 98%

N-Cholylglycine sodium salt, 98%

Biochemical Assay Reagents

Sodium glycocholate hydrate, 98% is a bile acid derivative. Sodium glycocholate hydrate, 98% downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Sodium glycocholate hydrate, 98% inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Sodium glycocholate hydrate, 98% modulates related bile acid receptor signaling. Sodium glycocholate hydrate, 98% suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Sodium glycocholate hydrate, 98% can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

Cat. No.	Nombre del producto	Target	Research Area

HY-P3078

Amphomycin	Bacterial Antibiotic	Infection
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .

HY-P1674A

Murepavadin TFA 3 Publications Verification POL7080 TFA	Bacterial Antibiotic	Infection
Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific *antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa* with MIC₅₀ and MIC₉₀ values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .

HY-P1674

Murepavadin POL7080	Bacterial Antibiotic	Infection
Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific *antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa* with both MIC₅₀ and MIC₉₀ values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .

HY-P10027

Clovibactin	Antibiotic Bacterial	Infection
Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .

HY-P10027A

Clovibactin TFA	Antibiotic Bacterial	Infection
Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .

HY-P10209

Cilagicin	Antibiotic Bacterial	Infection
Cilagicin, a dodeca-lipodepsipeptide, is a Gram-positive active *antibiotic. Cilagicin has a dual polyprenyl phosphate binding mechanism that impedes resistance* development .

HY-P10211

Virgilagicin	Antibiotic Bacterial	Infection
Virgilagicin is a Gram-positive active *antibiotic* that has a dual polyprenyl phosphate binding mechanism that impedes resistance development .

HY-P5620

DFTamP1	Bacterial	Infection
DFTamP1 is an antimicrobial peptide against Staphylococcus aureus USA300 activity (MIC is 3.1 μM) .

HY-P10411

BING	Bacterial	Infection
BING is an antimicrobial peptide that can be isolated from Japanese medaka fish. BING shows a broad-spectrum toxicity against pathogenic bacteria including drug-resistant strains. BING induces a deregulation of periplasmic peptidyl-prolyl isomerases in gram-negative bacteria, and reduces the RNA level of cpxR, which plays a crucial role in the development of antimicrobial resistance .

HY-P10210

Paenilagicin	Antibiotic Bacterial	Infection
Paenilagicin is a Gram-positive active antibiotic with a unique diphosphorylated prenyl binding mechanism that does not induce drug resistance. Paenilagicin exhibits a MIC value of 2 μg/mL against multidrug-resistant Gram-positive bacteria .

HY-P11659

B26 peptoid	Antibiotic Bacterial	Infection
B26 peptoid is a ptoid *antibiotic. B26 peptoid exhibits excellent broad-spectrum activity and high selectivity toward a panel of Gram-positive and Gram-negative bacterial strains. B26 peptoid disrupts bacterial membranes and has bactericidal activity. B26 peptoid shows low propensity for bacterial drug resistance*. B26 peptoid can be used for the research of bacterial infection .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-N1423

Glycocholic acid 3 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor
Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-B1329

Apramycin sulfate 4 Publications Verification Nebramycin II sulfate	Microorganisms Classification of Application Fields Antibiotics Animal Husbandry Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification Cancer	Bacterial Antibiotic
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside *antibiotic* which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .

HY-W062216

2-Aminoimidazole	Infection Productos naturales Animals Classification of Application Fields Disease Research Fields Source Classification	Bacterial Arginase
2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a K_i of 3.6 mM .

HY-77641

Cinnamoylglycine	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Cinnamoylglycine is a human urinary metabolite and PPG analog. Cinnamoylglycine is a conjugate of cinnamic acid and glycine. Cinnamoylglycine is used as a urine marker. Cinnamoylglycine can be used in adipogenic differentiation studies .

HY-N1423A

Glycocholic acid sodium 3 Publications Verification	Triterpenes Structural Classification Terpenoids Endogenous metabolite Source Classification	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite
Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-106681

Lagosin Fungichromin; Pentamycin; Cogomycin	Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Disease Research Disease Research Fields Source Classification Cancer	Antibiotic Fungal
Lagosin (Fungichromin) is a polyene macrolide antibiotic. Lagosin has demonstrated broad-spectrum antifungal activity and is impervious to agent resistance .

HY-122071

Bicyclomycin	Structural Classification Microorganisms Antibiotics Other Antibiotics Source Classification	Antibiotic Bacterial
Bicyclomycin is an *antibiotic. Bicyclomycin exhibits selective antibacterial activity against Gram-negative bacteria such as Escherichia coli* and Klebsiella spp., with no cross-resistance. Bicyclomycin is applicable to the research of infectious diseases .

HY-N1423B

Glycocholic acid hydrate 3 Publications Verification	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite Caspase G protein-coupled Bile Acid Receptor 1 LPL Receptor MDM-2/p53 Bcl-2 Family P-glycoprotein FXR Bacterial Apoptosis
Glycocholic acid hydrate is a bile acid derivative. Glycocholic acid hydrate downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid hydrate inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid hydrate modulates related bile acid receptor signaling. Glycocholic acid hydrate suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid hydrate can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-B1329R

Apramycin sulfate (Standard) Nebramycin II sulfate (Standard)	Structural Classification Microorganisms Antibiotics Animal Husbandry Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Antibiotic
Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .

HY-77641R

Cinnamoylglycine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Cinnamoylglycine (Standard) is the analytical standard of Cinnamoylglycine. This product is intended for research and analytical applications. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment .

HY-W062216R

2-Aminoimidazole (Standard)	Structural Classification Productos naturales Animals Source Classification	Reference Standards Bacterial Arginase
2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a Ki of 3.6 mM .

HY-N15123

Quinocycline B	Microorganisms Antibiotics Other Antibiotics Source Classification	Antibiotic Bacterial
Quinocycline B, a quinone-containing glycoside antibiotic, demonstrates resistance against Gram-positive bacteria .

HY-N15073

4-Hydroxyphlebiarubrone	Quinones Structural Classification Microorganisms Benzene Quinones Source Classification	Antibiotic Bacterial
4-Hydroxyphlebiarubrone is a quinone antibiotic. 4-Hydroxyphlebiarubrone has weak resistance to Gram-negative bacteria and cytotoxicity .

HY-N1423AR

Glycocholic acid sodium (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Reference Standards P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite
Glycocholic acid (sodium) (Standard) is the analytical standard of Glycocholic acid sodium (HY-N1423A). This product is intended for research and analytical applications. Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

Cat. No.	Nombre del producto	Chemical Structure

HY-N1423S

Glycocholic acid-d4

Glycocholic acid-d₄ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-B1455S1

Clindamycin-13C,d3

Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-77641S

Cinnamoylglycine-d2
Cinnamoylglycine-d₂ is the deuterium labeled Cinnamoylglycine. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment .

HY-B1455S

Clindamycin-d3 hydrochloride

Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-N1423S1

Glycocholic acid-d5

Glycocholic acid-d₅ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-W754548

Glycocholic acid-13C2,d4

Glycocholic acid- ¹³C₂,d₄ is the deuterium labeled and ¹³C-labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

Cat. No.	Nombre del producto		Classification

HY-152296

8-Methyladenosine		Nucleoside Analogs Adenosine
8-Methyladenosine is a modified adenosine nucleoside. Through methylation at the 8-position, 8-Methyladenosine confers bacterial resistance to five classes of antibiotics that bind to the ribosomal peptidyl transferase center. 8-Methyladenosine can be used in studies of antibiotic-resistant bacterial infections .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

Antibiotic resistance

Inhibitors & Agonists

Bibliotecas de Screening

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products